title: Tumor site-specific silencing of NF-kappaB p65 by targeted hollow gold nanosphere-mediated photothermal transfection.
abstract: NF-kappaB transcription factor is a critical regulator of the expression of genes involved in tumor formation and progression. Successful RNA interference (RNAi) therapeutics targeting NF-kappaB is challenged by small interfering RNA (siRNA) delivery systems, which can render targeted in vivo delivery, efficient endolysosomal escape, and dynamic control over activation of RNAi. Here, we report near-IR (NIR) light-inducible NF-kappaB downregulation through folate receptor-targeted hollow gold nanospheres carrying siRNA recognizing NF-kappaB p65 subunit. Using micro-positron emission tomography/computed tomography imaging, the targeted nanoconstructs exhibited significantly higher tumor uptake in nude mice bearing HeLa cervical cancer xenografts than nontargeted nanoparticles following i.v. administration. Mediated by hollow gold nanospheres, controllable cytoplasmic delivery of siRNA was obtained on NIR light irradiation through photothermal effect. Efficient downregulation of NF-kappaB p65 was achieved only in tumors irradiated with NIR light but not in nonirradiated tumors grown in the same mice. Liver, spleen, kidney, and lung were not affected by the treatments, in spite of significant uptake of the siRNA nanoparticles in these organs. We term this mode of action "photothermal transfection." Combined treatments with p65 siRNA photothermal transfection and irinotecan caused substantially enhanced tumor apoptosis and significant tumor growth delay compared with other treatment regimens. Therefore, photothermal transfection of NF-kappaB p65 siRNA could effectively sensitize the tumor to chemotherapeutic agents. Because NIR light can penetrate the skin and be delivered with high spatiotemporal control, therapeutic RNAi may benefit from this novel transfection strategy while avoiding unwanted side effect.
authors.affiliation: Department of Experimental Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
authors.forename: Wei
authors.initials: W
authors.lastname: Lu
authors.forename: Guodong
authors.initials: G
authors.lastname: Zhang
authors.forename: Rui
authors.initials: R
authors.lastname: Zhang
authors.forename: Leo G
authors.initials: LG
authors.lastname: Flores
authors.forename: Qian
authors.initials: Q
authors.lastname: Huang
authors.forename: Juri G
authors.initials: JG
authors.lastname: Gelovani
authors.forename: Chun
authors.initials: C
authors.lastname: Li
mesh_terms: D000818:Animals; D003593:Cytoplasm / Q000378:metabolism; D020868:Gene Silencing; D006046:Gold / Q000737:chemistry*; D006367:HeLa Cells; D006801:Humans; D008027:Light; D008247:Lysosomes / Q000378:metabolism; D053768:Metal Nanoparticles / Q000737:chemistry*; D051379:Mice; D008819:Mice, Nude; D054118:Nanospheres / Q000737:chemistry*; D009368:Neoplasm Transplantation; D034741:RNA, Small Interfering / Q000378:metabolism; D051996:Transcription Factor RelA / Q000737:chemistry* / Q000235:genetics*
chemical_list: D034741:RNA, Small Interfering; D051996:Transcription Factor RelA; D006046:Gold
references.citation: Angew Chem Int Ed Engl. 2005 Feb 18;44(9):1328-32
references.pmid: 15643658
references.citation: Biochim Biophys Acta. 2006 Mar;1758(3):394-403
references.pmid: 16497269
references.citation: Nat Rev Cancer. 2002 Apr;2(4):301-10
references.pmid: 12001991
references.citation: J Cell Sci. 1993 Sep;106 ( Pt 1):423-30
references.pmid: 8270640
references.citation: ACS Nano. 2009 Jan 27;3(1):80-6
references.pmid: 19206252
references.citation: Biomaterials. 2009 Apr;30(10):1928-36
references.pmid: 19131103
references.citation: Chem Commun (Camb). 2005 May 7;(17):2247-9
references.pmid: 15856111
references.citation: J Phys Chem B. 2006 Oct 12;110(40):19935-44
references.pmid: 17020380
references.citation: Oligonucleotides. 2008 Jun;18(2):123-32
references.pmid: 18637730
references.citation: Nanomedicine (Lond). 2007 Oct;2(5):681-93
references.pmid: 17976030
references.citation: Nature. 2001 May 24;411(6836):494-8
references.pmid: 11373684
references.citation: Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9138-43
references.pmid: 12886020
references.citation: Nat Biotechnol. 2001 Apr;19(4):316-7
references.pmid: 11283581
references.citation: Clin Cancer Res. 2009 Feb 1;15(3):876-86
references.pmid: 19188158
references.citation: Gene Ther. 2005 Dec;12(24):1734-51
references.pmid: 16079885
references.citation: Clin Cancer Res. 2004 May 15;10(10):3333-41
references.pmid: 15161687
references.citation: ACS Nano. 2009 Jul 28;3(7):2007-15
references.pmid: 19527019
references.citation: Mol Cancer Ther. 2008 Jun;7(6):1730-9
references.pmid: 18566244
references.citation: J Am Chem Soc. 2006 Mar 22;128(11):3709-15
references.pmid: 16536544
references.citation: Annu Rev Immunol. 1998;16:225-60
references.pmid: 9597130
references.citation: Biochim Biophys Acta. 2007 May;1768(5):1211-7
references.pmid: 17343820
references.citation: J Immunol. 2006 Aug 1;177(3):1975-80
references.pmid: 16849511
references.citation: J Phys Chem C Nanomater Interfaces. 2007 Apr 6;111(17):6245-6251
references.pmid: 20165552
references.citation: Small. 2005 Mar;1(3):325-7
references.pmid: 17193451
references.citation: Proc Natl Acad Sci U S A. 2007 Sep 25;104(39):15549-54
references.pmid: 17875985
references.citation: Nanotechnology. 2008 Jan 9;19(1):015701
references.pmid: 21730542
references.citation: Proc Natl Acad Sci U S A. 2003 Nov 11;100(23):13549-54
references.pmid: 14597719
references.citation: Nano Lett. 2006 Apr;6(4):662-8
references.pmid: 16608261